A new study has identified four main categories of cancer mutations that cause drug resistance, providing insights for drug development and potential second-line therapies. By using CRISPR gene editing, researchers mapped the genetic landscape of drug resistance in colon, lung, and Ewing sarcoma cancers. The study found that mutations can lead to drug resistance, drug addiction, driver mutations, or drug sensitizing variants, impacting the effectiveness of treatments. Understanding these DNA changes can inform personalized therapies, identify biomarkers for treatment sensitivity, and aid in the development of new cancer drugs to prevent drug resistance. The study was published in Nature Genetics.
Source link
Genetic mapping study uncovers four main categories of cancer drug resistance mutations
